Pharma ADMET Testing Global Market Report 2024

The pharma admet testing market size has grown rapidly in recent years. It will grow from $8.62 billion in 2023 to $9.61 billion in 2024 at a compound annual growth rate (CAGR) of 11.5%.The expansion observed in the historical period can be ascribed to the increasing prominence of biopharmaceuticals and biosimilars, a surge in drug development initiatives, heightened awareness concerning drug safety, the globalization of clinical trials, and a notable shift towards in silico modeling.

The pharma admet testing market size is expected to see rapid growth in the next few years. It will grow to $14.87 billion in 2028 at a compound annual growth rate (CAGR) of 11.5%. The anticipated expansion in the forecast period can be credited to factors such as increased emphasis on environmental toxicology and safety assessment, heightened awareness of pharmacogenomics, a strategic focus on precision medicine, the growing prevalence of biologics and biosimilars, the integration of artificial intelligence (AI), heightened regulatory requirements, and an upswing in orphan drug development. Notable trends expected in the forecast period encompass a rise in collaborative research efforts, rapid technological innovations, advancements in analytical technologies, ongoing vigilance in drug safety monitoring, and a heightened consideration of environmental impacts.

The upward trend in product approvals is a key driver for the pharma ADMET testing market. Product approvals involve the regulatory endorsement by authorities such as the Food and Drug Administration (FDA) in the United States or the European Medicines Agency (EMA) in Europe, allowing products to be marketed to the public. ADMET testing plays a crucial role in assessing the safety and efficacy of new products, and its inclusion is mandatory in the regulatory approval process. Notably, the Center for Drug Evaluation and Research reported that in 2020, 53 drugs received approval in the United States, indicating an increase from the 48 drugs approved in 2019. Consequently, the growing number of product approvals serves as a catalyst for the pharma ADMET testing market.

The surge in clinical trials is expected to drive the pharma ADMET testing market's growth in the future. Clinical trials, essential research studies involving human participants, evaluate the safety, efficacy, and potential side effects of medical interventions, including new drugs, medical devices, diagnostic procedures, or treatment regimens. The escalating number of clinical trials significantly amplifies the demand for comprehensive assessments of drug safety and efficacy within the pharma ADMET testing market. For example, a report from Xtalks reveals that, as of May 2023, there are 452,604 registered clinical studies on ClinicalTrials.gov, indicating a notable increase from the over 365,000 trials recorded in early 2021. This uptick underscores the industry's growing need for tailored evaluations across diverse drug candidates and patient populations, thereby propelling the pharma ADMET testing market's expansion.

A prominent trend gaining traction in the pharma ADMET testing market is the focus on product innovations, with major companies introducing cutting-edge solutions to enhance their market position. Notably, Charles River Laboratories International Inc. and Valo Health Inc. launched Logica in April 2022 - an AI-based drug development solution. Leveraging Valo's Opal Computational Platform, Logica provides users with ADMET testing services and other drug delivery solutions. The solution incorporates industry-leading predictive models, chemical design and synthesis capabilities, DNA-encoded libraries, and in silico high-throughput screening. Charles River's expertise in various discovery optimization aspects, including high-throughput screening, medicinal chemistry, ADME, biology, pharmacology, safety testing, and IND submission, further enhances Logica's capabilities.

Major players in the pharma ADMET testing market are strategically engaging in partnerships to advance efforts in discovering allosteric drugs. An illustrative example is the collaboration between Excelra and HotSpot Therapeutics Inc. In May 2022, Excelra, specializing in accelerating drug discovery through advanced data science, partnered with HotSpot Therapeutics Inc., a biotechnology company focused on small molecule allosteric therapies. This strategic alliance involves integrating Excelra's product, GOSTAR, and its annotated datasets into HotSpot's machine learning (ML) and artificial intelligence (AI) models. GOSTAR, with insights into over 8 million small molecules, provides comprehensive information on chemical structures and various biological properties, facilitating the exploration and development of small molecule therapeutic candidates targeting challenging allosteric sites.

In September 2022, BioIVT, a prominent drug development solutions provider based in the United States, successfully completed the acquisition of XenoTech for an undisclosed sum. This strategic move is designed to enhance BioIVT's product portfolio by integrating XenoTech's capabilities and to facilitate the expansion of its product offerings into new geographic regions, thereby reaching a broader customer base. XenoTech, a respected US-based contract research organization, specializes in offering ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) testing services. This acquisition underscores BioIVT's commitment to strengthening its position in the drug development sector by incorporating complementary expertise and extending its reach to cater to evolving market demands.

Major companies operating in the pharma admet testing market report are Thermo Fisher Scientific Inc., Abbott Laboratories, The Merck Group, Laboratory Corporation of America Holdings, IQVIA Inc., PPD ICON PLC, Agilent Technologies Inc., Wuxi AppTec Co. Ltd., Catalent Inc., Covance Inc., Charles River Laboratories International Inc., Eurofins Scientific SE, Beckman Coulter Inc., Perkinelmer Inc., Bio-Rad Laboratories Inc., Albany Molecular Research Inc., Evotec A.G., CMIC Holdings Co. Ltd., Promega Corporation, Aptuit LLC, Symeres B.V., Biovia Corp., BioIVT LLC, Cyprotex Limited, InSphero AG, Admescope Ltd., Accelrys Inc.

Asia-Pacific was the largest region in the pharma ADMET testing market in 2023. The regions covered in the pharma admet testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pharma admet testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary categories of pharma ADMET testing include in vivo ADMET testing, in vitro ADMET testing, and in silico ADMET testing. In vivo ADMET testing involves the analysis of a drug's absorption, distribution, metabolism, excretion, and toxicity attributes within a living organism. Widely utilized throughout drug discovery and development phases, pharma ADMET testing plays a crucial role in pinpointing potential drug candidates endowed with favorable pharmacokinetic properties. Utilizing advanced technologies such as cell culture, high throughput, molecular imaging, and OMICS, pharma ADMET testing is pivotal in assessing systemic toxicity, renal toxicity, hepatotoxicity, neurotoxicity, and other relevant parameters. This comprehensive approach aids in the strategic identification of drug candidates that align with desired efficacy and safety profiles, thereby contributing to informed decision-making in the pharmaceutical business landscape.

The pharma ADMET testing market research report is one of a series of new reports that provides pharma ADMET testing market statistics, including the pharma ADMET testing industry's global market size, regional shares, competitors with a pharma ADMET testing market share, detailed pharma ADMET testing market segments, market trends, and opportunities, and any further data you may need to thrive in the pharma ADMET testing industry. This pharma ADMET testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pharma ADMET testing market consists of revenues earned by entities by providing services such as in vitro screening, in vitro metabolism, and metabolite testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The pharma ADMET testing market also includes the sales of membranes, buffer systems, and analytes that are used in the assays. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.